Validation study of colorectal cancer treatment effect prediction by metabolomic markers

Validation study of colorectal cancer treatment effect prediction by metabolomic markers - Validation study of colorectal cancer treatment effect prediction by metabolomic markers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037904

Enrollment

Registered

2019-09-03

Start date

2019-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histopathologically confirmed colorectal cancer 2.Curatively unresectable colorectal cancer 3.Patient who has measurable lesion(s) 4.Without prior chemotherapy 5.Performance status is 0 or 1 6.Primary organ function is maintained 7.Written informed consent for participation in the study is obtained prior to the study

Exclusion criteria

Exclusion criteria: 1.A case with double cancer 2.Patient who need additional drugs which affect the evaluation of anti-tumor effects of FOLFOIX +BV or CapeOX + BV. 3.Patients who are judged inappropriate by physician

Design outcomes

Primary

Measure	Time frame
Best clinical response (RECIST 1.1) Serum concentration of metabolomic markers	—

Secondary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactShinji Sugimoto

Keio university school of medicine Department of Clinical pharmacokinetics and pharmacodynamics

s.sugimoto@keio.jp81-3-5363-3706

Outcome results